Inventor · disambiguated record
Israel Lowy
Also filed as: LOWY ISRAEL
32 granted patents·20 pending applications·347 citations·filing 2004–2025
97Inventor score
Files withREGENERON PHARMA32UNIV MASSACHUSETTS5MEDAREX INC4AMBROSINO DONNA M3INOVIO PHARMACEUTICALS INC3
Top patents by PatentIndex Score
52 records- 0196US7625559B2Antibodies against Clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2005·Granted Dec 1, 2009·47 cites·4 claims
- 0296US7456264B2Human monoclonal antibodies against Bacillus anthracis protective antigenMEDAREX INC·Filed 2004·Granted Nov 25, 2008·88 cites·32 claims
- 0395US11919965B2Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodiesREGENERON PHARMA·Filed 2020·Granted Mar 5, 2024·7 cites·20 claims
- 0495US8980268B2Methods for treating cancer by administering an anti-Ang-2 antibodyREGENERON PHARMA·Filed 2013·Granted Mar 17, 2015·16 cites·26 claims
- 0594US12054557B2Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancerREGENERON PHARMA·Filed 2021·Granted Aug 6, 2024·4 cites·33 claims
- 0694US8257709B2Antibodies against Clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2009·Granted Sep 4, 2012·22 cites·23 claims
- 0794US7465446B2Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of diseaseMEDAREX INC·Filed 2004·Granted Dec 16, 2008·52 cites·19 claims
- 0893US7744875B2Surrogate therapeutic endpoint for anti-CTLA-4 based immunotherapy of diseaseMEDAREX INC·Filed 2008·Granted Jun 29, 2010·16 cites·10 claims
- 0992US8236311B2Antibodies against clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2009·Granted Aug 7, 2012·15 cites·25 claims
- 1091US11926668B2Anti-PD-1 antibodies for treatment of lung cancerREGENERON PHARMA·Filed 2022·Granted Mar 12, 2024·3 cites·30 claims
- 1189US9968674B2Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2014·Granted May 15, 2018·10 cites·16 claims
- 1289US9062111B2CTLA-4 antibody dosage escalation regimensNICHOL GEOFFREY M·Filed 2011·Granted Jun 23, 2015·17 cites·28 claims
- 1388US9963501B2B cell lineage based immunogen design with humanized animalsREGENERON PHARMA·Filed 2014·Granted May 8, 2018·6 cites·14 claims
- 1488US7611702B2TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapyMEDAREX INC·Filed 2006·Granted Nov 3, 2009·12 cites·20 claims
- 1586US11590223B2Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodiesREGENERON PHARMA·Filed 2019·Granted Feb 28, 2023·4 cites·53 claims
- 1684US11292842B2Anti-PD-1 antibodies for treatment of lung cancerREGENERON PHARMA·Filed 2018·Granted Apr 5, 2022·5 cites·29 claims
- 1784US8110194B2CTLA-4 antibody dosage escalation regimensNICHOL GEOFFREY M·Filed 2006·Granted Feb 7, 2012·9 cites·25 claims
- 1883US8609111B2Antibodies against clostridium difficile toxins and uses thereofAMBROSINO DONNA M·Filed 2012·Granted Dec 17, 2013·4 cites·30 claims
- 1980US9217029B2Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2013·Granted Dec 22, 2015·2 cites·25 claims
- 2079US10662244B2Methods for tumor treatment using CD3XCD20 bispecific antibodyREGENERON PHARMA·Filed 2015·Granted May 26, 2020·2 cites·17 claims
- 2178US11505600B2Methods of treating skin cancer by administering a PD-1 inhibitorREGENERON PHARMA·Filed 2019·Granted Nov 22, 2022·1 cites·20 claims
- 2277US10626168B2B cell lineage based immunogen design with humanized animalsREGENERON PHARMA·Filed 2018·Granted Apr 21, 2020·1 cites·18 claims
- 2375US2021269511A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2020·Application pending·0 cites
- 2473US2024209090A1Anti-pd-1 antibodies for treatment of lung cancerREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2573US2025051466A1Methods of Treating Multiple Myeloma with Bispecific Anti-BCMA x Anti-CD3 AntibodiesREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2672US10457725B2Methods of treating skin cancer by administering a PD-1 inhibitorREGENERON PHARMA·Filed 2017·Granted Oct 29, 2019·2 cites·18 claims
- 2772US8404820B2Human monoclonal antibodies against Bacillus anthracis protective antigenKELER TIBOR·Filed 2008·Granted Mar 26, 2013·0 cites·39 claims
- 2872US2023227542A1Methods of treating skin cancer by administering a pd-1 inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2969US9573999B2CTLA-4 antibody dosage escalation regimensMEDAREX LLC·Filed 2015·Granted Feb 21, 2017·1 cites·9 claims
- 3067US11439683B2Anti-angiogenic therapy of metastatic colorectal cancerREGENERON PHARMA·Filed 2019·Granted Sep 13, 2022·0 cites·8 claims
- 3167US2023165959A1Dosing Strategy that Mitigates Cytokine Release Syndrome for Therapeutic AntibodiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3266US2018208643A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2018·Application pending·0 cites
- 3365US9399674B2Human antibodies to Clostridium difficile toxinsREGENERON PHARMA·Filed 2013·Granted Jul 26, 2016·1 cites·7 claims
- 3465US2024043560A1Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 AntibodiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3564US12350318B2Combination therapy to treat brain cancerINOVIO PHARMACEUTICALS INC·Filed 2022·Granted Jul 8, 2025·0 cites·23 claims
- 3664US2025304714A1Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 AntibodiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3763US12473364B2Intralesional administration of PD-1 inhibitors for treating skin cancerREGENERON PHARMA·Filed 2019·Granted Nov 18, 2025·0 cites·31 claims
- 3863US2024270849A1Methods of treating cancer with bispecific egfr xcd28 antibodies alone or in combination with anti-pd-1 antibodiesREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3962US2025352620A1Combination therapy to treat brain cancerINOVIO PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4059US2016152694A1Antibodies against clostridium difficile toxins and uses thereofUNIV MASSACHUSETTS·Filed 2015·Application pending·0 cites
- 4158US10532096B2Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibodyREGENERON PHARMA·Filed 2018·Granted Jan 14, 2020·0 cites·32 claims
- 4256US2023323470A1Methods of treating cancer by administering a pd-1 inhibitorREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4356US2025346670A1Methods of treating cancer by administering a neoadjuvant pd-1 inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4456US2025270321A1Methods of treating lung cancer by administering a pd-1 inhibitorREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 4554US9926369B2Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibodyREGENERON PHARMA·Filed 2015·Granted Mar 27, 2018·0 cites·10 claims
- 4652US2021403567A1Methods of treating cervical cancer by administering a pd-1 inhibitorREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 4748US2022259313A1Administration of a pd-1 inhibitor for for treating skin cancerREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 4847US2021128710A1Combination therapy to treat brain cancerINOVIO PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4946US2007243184A1Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapyFISCHKOFF STEVEN·Filed 2006·Application pending·0 cites
- 5045US10525104B2Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancerREGENERON PHARMA·Filed 2015·Granted Jan 7, 2020·0 cites·3 claims
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Israel Lowy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →